JAGX Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
Jaguar Health, Inc. had $11.5M of revenue in fiscal 2025, down 1.5% on the year before. Over five years, revenue changed +4.2% a year on average.
Last close Β· Oct 23, 2026
$2.04
5.1%Hi! I read Jaguar Health, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β1.5%
No. Sales fell 1.5% last year.
Does it make a profit?
β465.4%
No. It lost money last year.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
0.0x
One share costs 0.0 times its yearly profit per share.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA Β· Jaguar Health, Inc. had $11.5M of revenue in fiscal 2025, down 1.5% on the year before. Over five years, revenue changed +4.2% a year on average. Its operating margin was β398.8%, down 135.1Β pts: of every 100 in sales, about β399 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Jaguar Health, Inc. lost $53.6M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Jaguar Health, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $17.1M | $5.5M | $6.5M | $8.0M | $1.0M |
| Interest coverage | β4.8x | β2.7x | β5.4x | β133.5x | β685.2x |
| Current ratio | 1.8x | 0.7x | 2.0x | 1.6x | 0.5x |
| Quick ratio | 1.5x | 0.5x | 1.3x | 1.1x | 0.3x |
| Total assets | $53.3M | $47.5M | $50.8M | $53.4M | $38.3M |
| Total liabilities | $41.4M | $48.8M | $45.9M | $44.4M | $57.0M |
| Shareholders' equity | $11.9M | β$1.4M | $4.9M | $6.5M | β$18.7M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Jaguar Health, Inc. passes 2 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 6 / 9 | 4 / 8 | 3 / 8 | 5 / 8 | 3 / 8 | 2 / 8 | 3 / 8 | 3 / 8 | 2 / 8 |
| Accruals ratio | β9.0% | β51.5% | β22.2% | β46.7% | β46.8% | 72.7% | 65.6% | 67.6% | β17.5% | β65.2% |
| Altman Z'' | β66.06 | β10.99 | β15.30 | β17.61 | β15.47 | β16.67 | β24.35 | β22.42 | β23.33 | β45.89 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $0.1M | $4.4M | $4.4M | $5.8M | $9.4M | $4.3M | $12.0M | $9.8M | $11.7M | $11.5M |
| Gross profit | $0.1M | $3.5M | $1.7M | $2.0M | $6.1M | $2.0M | $9.9M | $7.7M | $9.7M | $7.7M |
| Research and development | $7.2M | $4.3M | $5.2M | $5.8M | $6.4M | $15.1M | $17.6M | $18.6M | $16.5M | $25.0M |
| Operating income | β$13.6M | β$34.2M | β$30.8M | β$28.9M | β$26.6M | β$40.7M | β$34.4M | β$34.3M | β$30.8M | β$45.9M |
| Interest expense | $1.0M | $1.2M | $2.6M | $5.7M | $2.8M | $8.4M | $12.7M | $6.4M | $0.2M | $0.1M |
| Pretax income | β$14.7M | β$35.1M | β$32.1M | β$38.5M | β$33.8M | β$52.6M | β$48.4M | β$41.9M | β$39.3M | β$54.0M |
| Income tax | β | β$13.2M | β | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Net income | β$14.7M | β$22.0M | β$32.1M | β$38.5M | β$33.8M | β$0.1M | β$0.0M | β$0.0M | β$38.5M | β$53.6M |
| Net income to common | β$14.7M | β$22.0M | β$32.1M | β | β$38.6M | β$52.6M | β$47.5M | β$41.3M | β$38.5M | β$53.6M |
| Diluted EPS | β$1.35 | β$7.59 | β$153.27 | β$9.01 | β$3.00 | β$88.22 | β$36.18 | β$2,678.17 | β$130.69 | β$22.97 |
| Diluted shares | 0.01B | 0.00B | 0.00B | 0.00B | 0.01B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B |
| Cash flow | ||||||||||
| Cash from operations | β$14.4M | β$9.8M | β$22.7M | β$20.5M | β$15.3M | β$35.0M | β$33.1M | β$33.2M | β$29.4M | β$23.7M |
| Capital expenditure | $0.1M | β | $0.0M | β | $0.0M | $0.0M | $0.1M | β | $0.0M | β |
| Free cash flow | β$14.5M | β | β$22.7M | β | β$15.3M | β$35.0M | β$33.2M | β | β$29.4M | β |
| Depreciation and amortization | $0.0M | $0.6M | $1.3M | $1.7M | $1.7M | $1.7M | $2.0M | $2.0M | $1.9M | $1.9M |
| Stock-based compensation | $0.7M | $0.8M | $2.0M | $3.0M | $2.8M | $4.0M | $3.3M | $2.1M | $1.6M | $0.8M |
| Acquisitions | β | $1.6M | β | β | β | β | β | β | β | β |
| Share buybacks | β | β | $0.0M | β | β | β | β | β | β | β |
| Dividends and buybacks | β | β | $0.0M | β | β | β | β | β | β | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $1.0M | $0.5M | $2.6M | $3.5M | $8.1M | $17.1M | $5.5M | $6.5M | $8.0M | $1.0M |
| Total debt | $3.7M | $12.6M | β | β | β | β | β | β | β | β |
| Current assets | $2.6M | $3.8M | $8.1M | $9.5M | $17.8M | $28.4M | $22.3M | $28.0M | $32.2M | $20.3M |
| Current liabilities | $4.2M | $15.4M | $26.7M | $15.4M | $13.2M | $15.5M | $30.3M | $14.0M | $19.7M | $40.7M |
| Inventory | $0.4M | $2.1M | $3.3M | $2.1M | $2.8M | $4.9M | $7.0M | $9.2M | $10.3M | $8.6M |
| Property and equipment, net | $0.9M | $1.2M | $0.8M | $0.7M | $0.7M | $0.7M | $0.6M | $0.5M | $0.5M | $0.5M |
| Goodwill | $0.0M | $5.2M | $5.2M | β | β | β | β | β | β | β |
| Intangible assets | β | $33.4M | $31.7M | $26.0M | $24.3M | $22.7M | $22.4M | $20.1M | $18.5M | $16.0M |
| Total assets | $3.6M | $43.6M | $41.0M | $36.4M | $42.8M | $53.3M | $47.5M | $50.8M | $53.4M | $38.3M |
| Total liabilities | $6.0M | $26.4M | $26.7M | $15.8M | $25.6M | $41.4M | $48.8M | $45.9M | $44.4M | $57.0M |
| Shareholders' equity | β$2.5M | $17.3M | $5.4M | $10.7M | $17.2M | $11.9M | β$1.4M | $4.9M | $6.5M | β$18.7M |
| Margins | ||||||||||
| Gross margin | 63.3% | 79.8% | 37.4% | 33.9% | 65.1% | 46.2% | 83.1% | 79.1% | 83.3% | 67.2% |
| Operating margin | β9,601.4% | β785.3% | β698.0% | β501.3% | β283.9% | β939.1% | β287.8% | β351.3% | β263.8% | β398.8% |
| EBITDA margin | β9,567.8% | β771.9% | β668.1% | β471.2% | β265.5% | β899.4% | β271.3% | β330.7% | β247.5% | β382.2% |
| Net margin | β10,412.6% | β503.7% | β727.9% | β667.3% | β360.2% | β1.2% | β0.4% | β0.4% | β329.3% | β465.4% |
| FCF margin | β10,260.0% | β | β514.9% | β | β162.9% | β806.8% | β277.5% | β | β251.5% | β |
| Returns | ||||||||||
| Return on capital | β3,232.8% | β92.2% | β | β | β | β | β | β | β | β |
| Return on capital employed | 2,157.2% | β121.3% | β214.3% | β137.7% | β90.0% | β107.7% | β201.1% | β93.2% | β91.4% | 1,969.5% |
| Return on equity | β | β296.7% | β283.9% | β480.1% | β242.6% | β0.4% | β0.9% | β2.4% | β675.8% | β |
| Return on assets | β413.5% | β93.1% | β75.9% | β99.5% | β85.3% | β0.1% | β0.1% | β0.1% | β73.9% | β116.8% |
| Growth | ||||||||||
| Revenue growth | β | 2,982.1% | 1.3% | 30.8% | 62.5% | β53.8% | 175.8% | β18.4% | 19.8% | β1.5% |
| Share count change | β | β73.6% | β92.8% | 2,267.8% | 159.4% | β95.4% | 120.0% | β98.8% | 1,812.3% | 692.0% |
| Financial health | ||||||||||
| Debt / equity | β | 0.7x | β | β | β | β | β | β | β | β |
| Interest coverage | β13.8x | β28.3x | β11.7x | β5.1x | β9.5x | β4.8x | β2.7x | β5.4x | β133.5x | β685.2x |
| Current ratio | 0.6x | 0.2x | 0.3x | 0.6x | 1.3x | 1.8x | 0.7x | 2.0x | 1.6x | 0.5x |
| Quick ratio | 0.5x | 0.1x | 0.2x | 0.5x | 1.1x | 1.5x | 0.5x | 1.3x | 1.1x | 0.3x |
| Capital allocation | ||||||||||
| Capex / revenue | 73.6% | β | 0.1% | β | 0.1% | 0.1% | 0.6% | β | 0.1% | β |
| Stock comp / revenue | 507.3% | 18.7% | 45.8% | 51.8% | 30.1% | 91.7% | 27.8% | 21.6% | 14.0% | 7.2% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 6.0 | 4.0 | 3.0 | 5.0 | 3.0 | 2.0 | 3.0 | 3.0 | 2.0 |
| Altman Z'' | β66.1 | β11.0 | β15.3 | β17.6 | β15.5 | β16.7 | β24.4 | β22.4 | β23.3 | β45.9 |
| Accruals ratio | β9.0% | β51.5% | β22.2% | β46.7% | β46.8% | 72.7% | 65.6% | 67.6% | β17.5% | β65.2% |
Source: SEC EDGAR XBRL filings (CIK 0001585608). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
